euroPLX 56 France 2014

euroPLX cycles stand for continuous business development and pharma deals since almost 20 years. Each cycle culminates in a conference after an extensive period of partnering information exchange.

euroPLX cycles are typically attended by business development decision makers, CEOs, owners, vice presidents, directors, and BD&L managers with decision power of drug developing, producing or marketing companies who look for new business opportunities. Brokers or consultants are admitted provided that they have clear, relevant mandates. euroPLX delivers an average of 23 to 27 or more pre-scheduled appointments per participating company.

Partnering scope: Registrants determine the Dynamic Partnering Focus of this cycle and conference. It is displayed on the right side of this page and evolves and changes over time when new data are entered by the delegates.

In addition to the displayed categories, participating companies may offer or look for R&D services, supporting technologies (new drug delivery; medical devices), contract manufacture, and, to some extent, the supply of APIs and intermediates.